Author:
Angioni Davide,Ousset Pierre-Jean,Vellas Bruno
Reference5 articles.
1. Drugs for Alzheimer’s disease: Where are we coming from? Where are we going?;Angioni;Science Bulletin (Beijing),2024
2. Designing the next-generation clinical care pathway for Alzheimer’s disease;Hampel;Nature Aging,2022
3. Trends in dementia incidence and mortality, and dynamic changes in comorbidity and healthcare utilization from 2004 to 2017: A Taiwan national cohort study;Huang;Archives of Gerontology and Geriatrics,2024
4. Challenges in developing geroscience trials;Rolland;Nature Communications,2023
5. CTAD Task Force paper: Neuropsychiatric symptoms in AD: Clinical trials targeting mild behavioral impairment: A report from the International CTAD Task Force;Soto;The Journal of Prevention of Alzheimer’s Disease,2024